The official Conference language is English, however where indicated, the sessions presented in Japanese will be translated consecutively into English

Japan boasts a strong patented pharmaceutical sector, which accounts for over 85% of the total market’s value. Consumption in general is boosted by an aging population and traditionally high use of medicines. Despite the global financial crisis, it was valued at over US$107 billion in 2010. This makes the Japanese market is the second largest in the world, behind USA but ahead of Germany.

Japan has had a mythical nature to its culture and this has traditionally posed as a hindrance for MNCs to enter the market. With the accumulation of years of stagflation, an aging population as well as the devastating tsunami, the Japanese government has to be more prudent in its spending in the healthcare sector, thus changing its policies.

Drug Discovery & Development Japan is part of IBC’s longest running DDT brand and will continue to address the latest concerns of the Japanese as well as global pharmaceutical companies. Japanese Pharma companies are increasingly open to partnerships to expand their exposure globally, signaling the best time for internationals to enter into the market. With a focus on partnerships, clinical trials and biologics R&D, Drug Discovery & Development Japan will provide the platform for networking as well as an insight into the Japanese markets for MNCs wanting to learn more.

Keynote Presentations
Dr Nobuo Hanai
Kyowa Hakko Kirin
Norikazu Eiki
Bayer Yakuhin

Country Spotlights

Dinesh Dua
Nectar Lifesciences

Youling Wu
Zhejiang Teruisi

Case Studies
  • Dr Reddy's and Fujifilm's Generic Partnership

  • Research into EGFR-targeting Biobetters Monoclonal Antibody

  • Kyowa Hakko Kirin’s Venture with Fujifilm into Biosimilars

New in 2012
  • EXCLUSIVE insights from Japan pharma plus simultaneous translation provided

  • ONLY conference in Japan with multi-player perspectives: Innovators + Biopharmas + Biosimilars

  • STRATEGIC FOCUS: Identifying successful strategies for partnerships and global expansion

  • EMPHASIS on Japanese and global interest into biologics R&D and approaches to optimize potential opportunities for sustainable growth

  • UNIQUE in-depth case studies on cross-border collaborations, lucrative research into bioproducts

  • MORE Asian speakers alongside their Western and Japanese Pharma counterparts

Pre-Conference Half-Day Workshop A
11 June 2012

Strategies and Tactics for the Development of Novel Biologics and Biosimilars
Led by: Dr Janet M McNicholas, Partner, K&L Gates LLP


Post-Conference Full Day Workshop B
14 June 2012

Understanding and Developing a Strategic Approach to China
Led by: Guang Yang, Senior Principal, Management Consulting, IMS Health China
Shaoyu Chen, Managing Director, China Food and Drug Practice, Covington & Burling LLP

Read more.

Top Reasons To Attend
  • Explore the move into big molecules – What are the risks?

  • Gather the latest insights from regional companies and MNCs about their strategic decisions and how they are positioning themselves for success

  • Learn from and personally meet senior executives from the major stakeholders from local Japanese to multinational companies

  • Expansion through partnerships – what are the factors driving this?

Share |

Register Online
Download Brochure

+65 6508 2401
+65 6508 2407
Email Customer Service

Other languages

- Meena Augustus, Ph.D., 科学顧問 , Shreis Health

Produced By



Knowledge Partner:

Silver Sponsor: Literature Sponsors:    


Media Partners

International Marketing Partner:

2012 © IBC Asia (S) Pte Ltd Registration Hotline: +65 6508 2401